| 產(chǎn)品編號(hào) | bs-37015R |
| 英文名稱 | Enfuvirtide Rabbit pAb |
| 中文名稱 | 恩夫韋肽抗體 |
| 別 名 | en-FYOO-veer-tide; Fuzeon; T-20; 159519-65-0; Enfuvirtide, Acetate; |
| 產(chǎn)品類型 | 小分子抗體 |
| 研究領(lǐng)域 | 免疫學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | (predicted: Enfuvirtide) |
| 產(chǎn)品應(yīng)用 | ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 4.49 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Liquid |
| 濃 度 | 1mg/1ml |
| 免 疫 原 | KLH conjugated synthetic peptide Enfuvirtide |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche). |
